HSKA
Undervalued by 18.6% based on the discounted cash flow analysis.
Market cap | $1.31 Billion |
---|---|
Enterprise Value | $1.30 Billion |
Dividend Yield | $0.3 (0%) |
Earnings per Share | $-1.78 |
Beta | 1.6 |
Outstanding Shares | 10,390,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -67.36 |
---|---|
PEG | 3203.17 |
Price to Sales | 5.0 |
Price to Book Ratio | 3.0 |
Enterprise Value to Revenue | 5.1 |
Enterprise Value to EBIT | -67.86 |
Enterprise Value to Net Income | -67 |
Total Debt to Enterprise | 0.09 |
Debt to Equity | 0.27 |
No data
No data
Heska Corporation manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instr...